- In addition to vaccines, it is now the turn of antibodies treatment to play a role in fighting COVID.
- There are also the diagnostics developers that still have an important stake in enabling recovery in intercontinental travel through rapid testing.
- Political challenges remain but, it is unlikely that there will be drastic policy reviews until Democrats have the power to carry out sweeping changes.
- XLV provides exposure to three vaccine and antibody treatment plays who have already made it to approval stage with Johnson & Johnson closely following.
- There should be an upside based on an update by JP Morgan that major pharma is trading at 35% discount.
For further details see:
Health Care Select Sector SPDR ETF: An Arsenal Of Therapies To Conquer COVID